Velox Q2/Q3 2018 Newsletter

22 October 2018
2 Views
Comments are off for this post

After we highlighted our Point-of-care UTI Screening and Antibiotic Resistance Test project in the last Velox newsletter, a top global diagnostics company contacted us unexpectedly. They acknowledged that UTI represents a very significant, but somewhat neglected market opportunity, and that they have been looking for solutions for the point-of-care setting. Learn more about Velox’s recent progress in developing solutions for UTI screening and rapid antibiotic resistance testing along with other applications of our platform technology in our Q2/Q3 2018 newsletter.